Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Clinical trial NCT05891821 · RECRUITING
Trial details
- NCT number
- NCT05891821
- Sponsor
- Immune Oncology Research Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-01
- Primary completion
- 2029-09-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.